Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 1
Guidelines for the Management of Constipation in Palliative Care
D Monnery,1 M Cooper,
1 R Ayre,
2 S Cureton,
2 L Devlin,
3 T Cookson,
3 C Owens,
3 S Schofield,
3 G
Sudworth,3 C Hyland,
3 L Edmunds,
1 L Waters,
1 A Scott.
4 (Guideline Development Lead).
1 The
Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.
2Bridgewater Community Healthcare NHS Foundation
Trust, Wigan, UK. 3Willowbrook Hospice, Prescot, Merseyside, UK.
4Marie Curie Hospice, Liverpool, UK.
Summary of Main Recommendations
Diagnosis Constipation is a very common symptom in palliative care patients which can adversely
affect their quality of life. Patients and healthcare professionals often differ in their assessment.3 [Level 3] It is important to explore the views of the patient and whether they believe themselves to be constipated. 3 [Level 3]
The Bristol Stool Chart may be useful in helping to make a diagnosis of constipation. Assessment Before starting any laxative medicine clinical assessment should exclude bowel
obstruction. It may be appropriate to check the patient’s blood biochemistry and perform a digital rectal
examination. Health professionals should assess for any factors potentially contributing to the
constipation including: opioids;14 [Level 2+] mobility; fluid / dietary intake and environmental factors such as equipment needs.15 [Level 4]
Symptom Control Always give advice about non pharmacological measures. Further guidance on dietary
advice can be found in Section 4.4 of this guideline. Laxative monotherapy should be used where possible, as it may avoid tablet burden and
improve quality of life for the patient.25 [Level 4] The evidence base for the use of some laxatives is limited. Senna and lactulose have
been shown to be effective when used as single agents and in combination.4,24 [Level 1] Other laxatives may also be considered. Please see Figure 1 and Table 3 in the guideline.
If constipation persists despite the optimisation of oral laxatives, rectal interventions may be considered. A digital rectal examination will help to determine the most appropriate rectal intervention to use. Please see Figure 2.
For patients with malignant spinal cord compression, rectal intervention should be given on alternate days and combined with an alternate day stimulant oral laxative such as senna.15 [Level 4] Please see Figure 2.
Communication Patients should be offered information about constipation at the time of diagnosis, and
when starting any medicines which increase the risk of constipation e.g.opioids.15 [Level 4]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 2
Section 1: Introduction
Constipation is a very common symptom in palliative care patients.1 It has been
shown to result in significant physical, psychological, social and existential
problems affecting quality of life.2
Defining constipation is complicated by conflicting perceptions between patients
and clinicians. Patients frequently describe constipation as an experience of
bowel movements. Clinicians may define constipation based on the frequency of
bowel movements.3 In general, the various definitions of constipation refer to:
infrequent, difficult or incomplete bowel evacuation that may lead to pain and
discomfort; stools that can range from small hard ‘rocks’, to a large bulky mass;
and a sensation of incomplete evacuation.4
Due to the difficulties in defining constipation, the incidence is difficult to
determine but has been estimated at between 18% and 90% of patients receiving
palliative care.5-7 The prevalence of contributory factors is estimated at between
25% and 90% of patients.1,8
The lack of a clear definition of constipation can contribute to difficulties and
delays in reaching a diagnosis.9 No tools or criteria have been demonstrated to
be consistently effective in helping to make an accurate diagnosis of constipation
in patients receiving palliative care.
Causes of constipation in the palliative care population are often multifactorial
and include: poor dietary intake; physical inactivity; disease related and treatment
related.4 The prevention and treatment of constipation is often related to the
cause.4 Constipation in the majority of people receiving palliative care has the
potential to be drug-induced and so management to promote satisfactory bowel
movements commonly involves laxative administration.4,10
The benefits of treatment must be balanced against potential side effects. Many
laxatives can contribute to discomfort by exacerbating colic or causing diarrhoea.
Use of rectal interventions has implications for dignity and may not be acceptable
to some patients. Management options should be discussed with the patient and
/or those important to them, taking full account of their views and preferences.
This guideline aims to give advice about the diagnosis, assessment and use of
pharmacological and non-pharmacological measures which can be offered to
relieve constipation in patients receiving palliative care. It is an update of
“Guidelines for the Management of Constipation in Palliative Care” last reviewed
in 2010.1 Management of bowel obstruction in palliative care is available
separately and not covered in this guideline.12
Section 2: Scope and Purpose
This guideline aims to inform practice in the assessment, diagnosis and
management of constipation in patients receiving palliative care.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 4
The guideline is aimed at specialist palliative care professionals including doctors,
nurses, pharmacists and allied health professionals and generalists involved in
providing palliative care e.g. general practitioners, district nurses, hospital doctors
and nurses.This guideline is an update of Guidelines for the Management of
Constipation in Palliative Care, 2010.11
Due to differences in approach and treatment, management of bowel obstruction is
not covered in this guideline. There is a separate regional guideline for the medical
management of malignant bowel obstruction in palliative care.12
The guideline aims to answer the following questions:-
1. What is the best method to assess patients for the presence of constipation in
palliative care? 2. What methods of management are recommended in patients diagnosed with
constipation in palliative care?
Table 1 summarises the scope and purpose of this guideline.
Table 1 Scope of Guideline
Population People aged over 18 years with constipation receiving
palliative care
Populations not covered People under 18 years
People not receiving palliative care
Healthcare setting
Community care
Secondary care
Tertiary care
Hospice care
Topics Diagnosis and assessment of constipation in palliative
care
Management of constipation in palliative care
Topics not covered Bowel Obstruction
Section 3: Methods
This guideline is based on the AGREE II criteria, which can be found in the Cheshire
and Merseyside Palliative and End of Life Care Network Audit Group Guideline
Development Manual.13
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 4
3.1. Clinical Questions and Interventions
The clinical questions were derived from the previous guideline developed in 2008
and updated in 2010.11 These were refined by the Guideline Development Group
which has authored this guideline. The clinical questions used to guide the literature
review in PICO (Patient, Intervention, Control, Outcome) format are:-
1. In patients receiving palliative care and suffering from medication-induced
constipation (P), is one method of management (I) superior to other methods or
no formal method (C) in relieving constipation (O).
2. In patients receiving palliative care and suffering from non-medication-induced
constipation (P), is one method of management (I) superior to other methods or
no formal method (C) in relieving constipation (O).
3.2. Outcomes
To maximise patient comfort by ensuring the best assessment and treatment
methods for patients with constipation receiving palliative care through:-
improved knowledge of the assessment and diagnosis of constipation
improved knowledge of the non-pharmacological and pharmacological
interventions available
promotion of education and training for all staff involved in caring for patients with
constipation
3.3. Literature Search
Systematic electronic database searches were undertaken to find potentially relevant
articles. MEDLINE, Embase, CINAHL and Cochrane databases were searched in
July 2017. A full outline of the search strategy, results and appraisal of evidence can
be found in Appendix 1. The grading of the level of evidence and recommendations
follows the Cheshire and Merseyside Palliative and End of Life Care Network Audit
Group Guideline Development Manual and uses SIGN criteria.13
Section 4: Guideline Recommendations
4.1. Assessment and Diagnosis of Constipation
Assessment of constipation is complicated by a difference in perception and
definition between patients and clincians.14 Health professionals’ assessment of
whether a patient is constipated, often differs from that of the patient.3 [Level 3]
When assessing a patient and making a diagnosis of constipation it is important
to elicit the views of the patient and clarify whether or not they think they are
constipated.3 [Level 3]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 5
An assessment of a patient with suspected constipation should include details
of:-
Frequency of bowel movement
Ease of defecation
Consistency and volume of stool [Level 4]15
A Bristol Stool Chart which is based on stool consistency may also be of benefit
in reaching a diagnosis of constipation.15 [Level 4] A link to a copy of the Bristol
Stool Chart can be found here: [Link]
Clinical assessment should include a review of any medicines that may be
contributing to constipation, including opioids.14 [Level 2+]
Clinical assessment should also review non-pharmacological contributory factors
such as: mobility, fluid and dietary intake and environmental factors such as
equipment needs.15 [Level 4]
Health professionals should perform an abdominal examination before making a
diagnosis of constipation.15 [Level 4]
If a diagnosis of constipation is suspected, consider further investigations such as
[Level 4]15
Urea, electrolytes and adjusted calcium
Rectal examination
The assessment should aim to exclude bowel obstruction before starting
treatment.15 [Level 4]
4.2. The Mental Capacity Act, 2005
If a patient is shown to lack capacity to consent to treatment, the Mental Capacity
Act, 2005 must be followed. If the patient lacks capacity to make decisions about
their treatment, the known views of the patient should be explored, and the
reasoning behind best interest decision making documented. The known views of
the patient may be sought through the family, a nominated spokesperson or an
advance statement. [Level 4]16
Lasting Power of Attorney for Health and Welfare, Advance Decisions to Refuse
Treatment, Independent Mental Capacity Advocates and Deprivation of Liberty
Safeguards should be utilised where appropriate.16 [Level 4]
4.3. Preventing Constipation
Preventing constipation or treating it effectively once present, depends on being
able to identify those patients at risk. A retrospective cohort study included in this
review has identified risk factors for developing constipation from both the patient
and clinician perspective.14
For medical constipation (defined in this study as stool frequency <3 times per
week), risk factors for the development of constipation are: being bed restricted;
being treated on a palliative care ward; reduced fluid intake; needing assistance
with personal care and patient tried medical self-management. 14 [Level 2+]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 6
For patient perceived constipation (without reduction in stool frequency), risk
factors are: being bed restricted; poor appetite; haemorrhoids; no information
given on constipation; low satisfaction with information given on constipation; use
of opioids; use of paracetamol; and absence of regular laxatives.14 [Level 2+]
Statistically significant key risk factors (when all results are combined) are
detailed in Table 2.14 [Level 2+]
Table 2. Key risk factors for the development of constipation [Level 2+]14
Being treated in a palliative care ward Haemorrhoids Heart disease No information given on constipation No laxatives available on request
No regular laxative use Paracetamol Poor appetite Use of opioids
Patients who are likely to require higher doses of laxatives to effectively treat their
constipation are: female; those with abdominal disease; taking an opioid; older.17
[Level 2]
Risk factors should be recognised and corrected where possible at the earliest
opportunity to prevent constipation in high risk patients.15 [Level 4]
4.4 Non-Pharmacological Management
The non-pharmacological management of constipation should be tailored to any
reversible causes detected during the clinical assessment. [Level 4]15
Always give advice about: diet, fluid intake and mobility. Environmental factors
should also be discussed e.g. correct posture; suitable and accessible toilet
facilities (e.g. toilet seat raisers); allowing adequate time. Privacy and dignity
should always be maintained. Changes to a persons’ care and regimen should be
minimised in order to avoid constipation. For patients with constipation secondary
to spinal cord compression. it is important to maintain a regular schedule for
toileting.15 [Level 4]
Medications should be reviewed regularly to ensure that those which contribute to
constipation are minimised as much as possible [Level 4]15
Related factors such as reduced mobility, reduced food intake, weakness and
dehydration should be addressed where practical and appropriate.15 [Level 4]
4.4.1 Dietary advice
There is a lack of experimental studies assessing use of dietary fibre in the
management of constipation in the palliative care setting. Recommendations are
based on professional consensus and opinion.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 7
For palliative patients that are able to maintain nutritional status through oral diet
and fluids, patients are advised to aim for 30g fibre per day, including whole
grains, fruit and vegetables.18 [Level 4]
Dietary fibre consumption should be gradually increased over a number of days
to avoid gastrointestinal symptoms.18 [Level 4]
Information for healthcare providers and patients about high fibre diets is
available here. [Link] 18
The effects of increased fibre consumption may materialise over weeks and
should be monitored alongside any potential reduction in pharmacological
interventions. The average daily intake of dietary fibre in the UK is only 18g
Meeting the recommendation of 30g/day will potentially be a challenge for
patients.19 [Level 4]
The prescription of fibre containing complete oral nutritional supplements may be
considered. However their nutritional value may not be equivalent to non fibre
containing products.15 [Level 4]
A minimum daily fluid intake of 1.5 litres has been suggested but this may not be
realistic.20 Patients that are able to manage some oral dietary intake can
maximise their fluid intake with foods containing a higher water content e.g. fruit,
jelly, soups, sauces, mousses, ice cream, milky puddings and oral nutritional
supplements where appropriate. 21 [Level 4]
Patients that require a texture modified diet will potentially struggle to meet fluid
requirements and optimise their fibre intake. These patients should be considered
for referral to a dietetic service.15 [Level 4]
Patients who are in the last days or hours of life may not achieve adequate fluid
and fibre intake. It may be more realistic to review pharmacological
interventions.15 [Level 4]
Dietetic assessment and intervention should be considered to support patients
and those important to them in translating recommendations into practical steps,
enabling behaviour change and managing expectations. Fluid and nutritional
intake can be a source of conflict and this can be addressed by these skilled
professionals. [Level 4]15
4.5 Pharmacological Management
4.5.1 Management of General (non opioid induced) Constipation
In many palliative care settings, current practice in the management of
constipation is to use combination regimens. This often includes a stool softener
and a stimulant laxative22 although there is limited evidence to support this
approach.23 [Level 4]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 8
A recent Cochrane Review did not discover any experimental data where a single
laxative was compared against placebo.4 We can therefore only comment on the
apparent relative efficacy of medications for constipation. No Cochrane Reviews
have been able to recommend any one specific laxative for the management of
constipation in palliative care.4, 24
A combination of docusate and senna has been shown to be no more effective
than senna monotherapy. However this was only a single study so should be
interpreted with caution.25 [Level 1-]
Using laxative monotherapy where possible arguably also avoids tablet burden
and improves quality of life for patients.25 [Level 4]
Senna and lactulose monotherapy are equally effective.4,24 [Level 1] However
40% of patients treated with monotherapy then required senna and lactulose
combination therapy to relieve constipation. This suggests there is greater
efficacy with a combination regimen, although it was not statistically significant.4
Senna and lactulose combination therapy has been shown to be an effective
combination and has demonstrated superiority over paraffin, magnesium
hydroxide and co-danthramer.24 [Level 1]
Any increase in dose and addition of other laxatives should be undertaken
gradually to avoid side effects such as colic and diarrhoea. Side effects are more
common with higher doses and an increased numbers of laxatives.24 [Level 1]
Other medications such as macrogols, co-danthramer and magnesium hydroxide
are not widely tested in a palliative care population but may be considered based
on the experience of the prescriber.15 [Level 4]
The choice of laxative and risk of side effects should be discussed with the
patient, and their views taken into account when prescribing any medicines.15
[Level 4]
For non opioid-induced constipation, a trial of combination laxatives at optimal
doses should be followed by consideration of a rectal intervention unless there
are any contraindications.15 [Level 4]
In the inpatient setting, oral laxatives should be reviewed every 3-4 days until the
constipation has resolved.15 [Level 4]
Please see Figure 1 and Table 3 for advice on choice of laxative and dosage.26
[Level 4]
4.5.2. Management of opioid induced constipation
There is no evidence from this review that opioid rotation is more effective than
laxative use in the treatment of opioid induced constipation.24
Senna and lactulose combination therapy has been shown to be more effective
than co-danthramer monotherapy in the management of opioid induced
constipation at morphine equivalent doses of greater than or equal to 80mg/24h. 4 [Level 1]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 9
For patients with opioid induced constipation who do not respond sufficiently to
other laxatives (approximately 50% in one study 27), naloxegol is superior to
placebo in relieving constipation.27 [Level 1]
Naloxegol is more effective at higher doses, but titration should be undertaken
cautiously as side effects are also more common.27 [Level 1]
If treating opioid induced constipation naloxegol has been recommended by
NICE as a third line medicine when a trial of other laxatives has been
unsuccessful.28
If a patient with opioid induced constipation is unable to manage oral medication
methylnaltrexone has been shown to be effective.29,30 [Level 1]
If using methylnaltrexone, 0.15mg/Kg is an effective dose and the effect is
greater in those patients in whom opioid doses are higher. There are greater side
effects, but no greater efficacy associated with increasing the dose of
methylnaltrexone.30 [Level 1]
See Figure 1 and Table 3 for advice on choice of laxative and dosage.26 [Level 4]
4.5.3 Rectal Interventions
There is no experimental evidence to support the use of rectal interventions for
constipation, or to direct the choice of rectal intervention. The following guidance
is based on professional consensus and opinion.
The choice of rectal intervention should be based on the results of a digital rectal
examination. (see Figure 2).15 [Level 4].
For patients with malignant spinal cord compression, a rectal intervention should
be administered on alternate days and combined with an alternate day oral
stimulant laxative i.e. senna.15 [Level 4] Please see Figure 2 for details.
4.6 Communication and Information
Inadequate information about constipation and the risk factors is linked with a
higher number of patients developing constipation.14 [Level 2+]
Patients should be offered information about constipation at the time of diagnosis,
or the possibility of developing constipation when starting medicines which
increase this risk e.g. opioids.15 [Level 4].
Provision of information is currently lacking in UK practice. Written information
about constipation would benefit patients.3 [Level 3]
Verbal or written information on constipation should include; risk factors, advice
regarding self-care, the role of laxatives in managing constipation and when to
seek medical advice.15 [Level 4]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 10
Figure 1. Laxative choice for opioid induced 27 [Level 1] and non-opioid induced constipation 4,24, 25 [Level 1] (Use of Macrogols, Co-Danthramer, Magnesium hydroxide and Rectal interventions 15 [Level 4]).
LACTULOSE SENNA OR
Titrate dose
LACTULOSE SENNA AND
NALOXEGOL (or methylnaltrexone if not able to take orally)
Opioid Induced Constipation
Non-Opioid Induced
Constipation
Consider alternative laxative e.g. Macrogol, Co-Danthramer or
Magnesium Hydroxide based on local prescribing practices and in discussion with the patient. Seek
expert advice if unsure.
Titrate dose Titrate dose
RECTAL INTERVENTIONS (According to rectal
examination)
Titrate dose
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 11
Figure 2. Choice of rectal intervention in severe constipation15 [Level 4]
Rectal
Examination
Impacted Hard
Faeces
Impacted Soft
Faeces
Empty rectum plus
loaded colon
Bisacodyl plus glycerol
suppositories
Bisacodyl
suppository Phosphate enema
If ineffective use
enema
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 12
**Note: The choice of medicines mentioned in this review should be undertaken with consideration of local prescribing practices and policies and reference to dosing advice in the BNF26 and PCF531 and discussion with experts if required.
Table 3 Pharmacological Options for the Management of Constipation in Palliative Care 26, 31
**
Senna [Level 1] Lactulose [Level 1] Naloxegol (Moventig) [Level 1] Glycerol Suppositories [Level 4]
Bisacodyl suppositories [Level 4]
Starting dose and titration advice
Start with 15mg nocte. Increase to 15mg bd after 24-48h if no effect. If necessary increase to a maximum of 30mg tds.
Starting dose is 15ml bd of 10g/15mL solution. Titrate according to result. Maximum 45ml tds.
Start with 25mg once daily. Maintenance dose is 25mg once daily. Max dose 25mg od.
One 4g suppository to be used when required.
One 10mg suppository to be used when required.
Dosing in renal impairment
No dose adjustment required.
No dose adjustment required.
If creatinine clearance is less than 60 mL/min: Reduce starting dose to 12.5 mg orally once a day. May increase to 25 mg orally once a day as needed for symptoms, if tolerated.
No dose adjustment required.
No dose adjustment required.
Side effects Intestinal colic, diarrhoea, hypokalaemia in cases of profuse diarrhoea.
Abdominal bloating, flatulence, nausea, intestinal colic.
Diarrhoea, intestinal colic, nausea. Diarrhoea, faecal leakage. Diarrhoea, faecal leakage, local irritation.
Contra-indications
Intestinal obstruction. Intestinal obstruction Use with caution in lactose intolerance Use with caution in diabetes due to sugar content.
Intestinal obstruction. Concomitant use of potent CYP3A4 Inhibitors is contraindicated. Caution is advised if concomitant use with moderate CYP3A4 inhibitors.
Immediately post surgery involving pelvis.
Immediately post surgery involving pelvis.
Notes Nil. Can be used in those who experience colic with stimulant laxatives.
Only to be used if constipation is felt to be due to opioids. To be taken on an empty stomach, 1 hour before or 2 hours after eating.
15-30 minutes required to take effect.
20-45 minutes required to take effect.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 13
**Note: The choice of medications mentioned in this review should be undertaken with consideration of local prescribing practices and policies with due consideration to dosing advice in the BNF26 and PCF531 and discussion with experts if required.
Table 3 - (Continued). Pharmacological Options for the Management of Constipation in Palliative Care26, 31
**
Macrogols [Level 4] Co-Danthramer [Level 4] Magnesium Hydroxide [Level 4] Docusate Sodium [Level 4]
Starting dose and titration advice
Start with 1 sachet or 125ml of diluted oral liquid concentrate once a day. Increase to bd-tds if required.
If using Co-Danthramer strong suspension (75mg/5ml), start with 5ml nocte. If necessary, adjust every 2-3 days up to 10ml bd or 20ml nocte.
If used in combination with a stimulant laxative: 15-30ml bd. If used as monotherapy: 15-60ml bd.
Start with 100mg bd. If necessary increase to a maximum of 200mg tds
Dosing in renal impairment
No dose adjustment required. No dose adjustment required. Risk of hypermagnesaemia is increased in renal impairment.
No dose adjustment required
Side effects Abdominal bloating, discomfort, borborygmi, hyponatraemia, nausea.
Intestinal colic, diarrhoea, discoloured urine, perianal irritation.
Oral magnesium salts act as antacids and the resulting increase in gastric pH may affect the absorption of other drugs if taken concurrently.
Diarrhoea, nausea, intestinal colic, rash.
Contra-indications
Stop if signs of fluid/electrolyte shift occur. Macrogol 3350 oral liquid is not authorised for faecal impaction.
Intestinal obstruction, non-terminal disease.
Hypermagnesaemia. Complete intestinal obstruction.
Notes Onset of action is 1-2 days for constipation.
UK marketing authorisations for laxatives containing dantron are limited to constipation in terminally ill patients.
Nil. Can be used in persistent partial bowel obstruction.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 14
Section 5: Standards
1. A clinical assessment should be completed and documented. The cause(s) of
constipation should be documented. If an assessment cannot be made, the
reason should be documented. [Grade D]15
2. Before treating constipation, bowel obstruction should be excluded in all patients.
[Grade D]15
3. All patients commencing opioid therapy should be offered laxative monotherapy.
[Grade D]15
4. A digital rectal examination should be performed before giving any rectal
intervention for constipation. [Grade D]15
Section 6: Applications and Implications
The aim is to re-audit practice once change has been implemented. This guideline
will be supplemented with the development of a patient information leaflet on
constipation which will include risk factors, self-care, pharmacological management
and advice on when to seek medical review.
This review has highlighted a number of unanswered questions in the research
literature. It is hoped that further research on the efficacy of many laxatives in the
palliative care population may be conducted in the future, as well as studies to
improve the definition of constipation and enhance the development of diagnostic
tools.
This guideline formed the basis of an abstract submission to the Association for
Palliative Medicine 2018 Supportive and Palliative Care Conference to share the
work and lessons learned to a wider audience.
Section 7: Acknowledgments and Declarations of Interest
Authors
Dr Dan Monnery, Specialty Registrar in Palliative Medicine, The Clatterbridge
Cancer Centre NHS Foundation Trust and Woodlands Hospice, Aintree,
Liverpool.
Mr Malcolm Cooper, Clinical Nurse Specialist in Palliative Care, The Clatterbridge
Cancer Centre NHS Foundation Trust.
Ms Rachael Ayre, Clinical Nurse Specialist in Palliative Care, Bridgewater
Community Healthcare Foundation Trust, Wigan.
Dr Susan Cureton, Specialty Doctor in Palliative Medicine, Bridgewater
Community Healthcare Foundation Trust, Wigan.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 15
Ms Lucy Devlin, Staff Nurse, Willowbrook Hospice, Prescot, Merseyside
Ms Tracey Cookson, Staff Nurse, Willowbrook Hospice, Prescot, Merseyside.
Ms Catherine Owens, Staff Nurse, Willowbrook Hospice, Prescot, Merseyside
Ms Susan Schofield, Staff Nurse, Willowbrook Hospice, Prescot, Merseyside
Ms Gemma Sudworth, Staff Nurse, Willowbrook Hospice, Prescot, Merseyside.
Mr Charles Hyland, Senior Staff Nurse, Willowbrook Hospice, Prescot,
Merseyside.
Ms Lauren Edmunds, Macmillan Oncology Dietician, The Clatterbridge Cancer
Centre NHS Foundation Trust.
Ms Liz Waters, Macmillan Dietician Team Leader, The Clatterbridge Cancer
Centre NHS Foundation Trust.
Dr Aileen Scott, Consultant in Palliative Medicine, Marie Curie Hospice, Liverpool
(Guideline Development Lead).
Contributors
The Guideline Development Group gratefully acknowledges the work of the following
people in supporting the development of this guideline:-
Dr Katie Frew, Consultant in Palliative Medicine, Northumbria Healthcare NHS
Foundation Trust for her expert external review of this guideline.
Dr Martyn Dibb, Consultant in Gastroenterology, Royal Liverpool University
Hospital for his expert input to the development of this guideline.
Angela Fell, for her contribution as patient, carer and public representative.
Members of the Cheshire and Merseyside Palliative and End of Life Care
Network Audit and Clinical Guideline Group who submitted data for the regional
audit on the management of constipation and contributed to guideline
development through expert opinion.
Dr M Brooks, Dr F Ahmad, Mr A Dickman, Dr CM Littlewood, Dr M Makin, Mrs C Duddle and Dr N Sykes who authored the 2008 guideline.
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 16
Development of the guideline was funded through the use of supporting professional
activity time facilitated by the employing organisations of the authors. The authors
and reviewers declare no conflicting interests.
The authors contributed as follows:-
Literature review: DM, RA, CO, CH, GS, LD, LE, LW.
Audit tools: AS, MC, SS, SC, TC
Updated guidance and grading recommendations: DM, AS, MC, RA
Standards: DM, AS, MC, RA
Final writing of manuscript of guidelines: DM, MC, CO, SS, LE, LW, AS.
Section 8: Review Date
The guideline will be reviewed three years after publication as outlined in the
Cheshire and Merseyside Palliative and End of Life Care Network Audit Group
Guideline Development Manual.
Section 9: References
1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The
prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a
US and European patient survey (probe 1). Pain Med, 2009; 10: 35–42. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/18721170 [Last accessed 15 July
2018]
2. Friedrichsen M, Erichsen E. The lived experience of constipation in cancer
patients in palliative hospital-based home care. Int J Palliat Nurs, 2004; 10: 321–
325.Available at:
https://www.magonlinelibrary.com/doi/abs/10.12968/ijpn.2004.10.7.14570?journal
Code=ijpn [Last accessed 15 July 2018]
3. Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a
survey of practices in the United Kingdom. J Pain Symptom Manage, 2005; 29:
238–24.Available at:
https://www.sciencedirect.com/science/article/pii/S0885392404005676 [Last
accessed 15 July 2018]
4. Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for
the management of constipation in people receiving palliative care (Review).
Cochrane Database of Systematic Reviews, 2015; 5: 1-31. Available at:
http://www.cochrane.org/CD003448/SYMPT_laxatives-for-the-management-of-
constipation-in-people-receiving-palliative-care [Last accessed 15 July 2018]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 20
5. Clark K, Currow DC. Assessing constipation in palliative care in a
gastroenterology framework. Palliat Med, 2012; 26: 834–84. Available at:
http://journals.sagepub.com/doi/abs/10.1177/0269216311414756?journalCode=p
mja [Last accessed 15 July 2018]
6. Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P. Research Steering
Committee of the EAPC. Intensity and treatment of symptoms in 3,030 palliative
care patients: a cross-sectional survey of the EAPC Research Network. Journal
of Opioid Management, 2009; 5:11–21. Available at:
http://www.eapcnet.eu/Themes/EAPCResearchNetwork/Publications/EAPCRese
archNetwork/tabid/275/ctl/Details/ArticleID/150/mid/1336/ [Last acccessed 15
July 2018]
7. Sykes N. The relationship between opioid use and laxative use in terminally ill
cancer patients. Palliat Med, 1998; 12:375–82. Available at:
http://journals.sagepub.com/doi/abs/10.1191/026921698674125048 [Last
accessed 15 July 2018]
8. Hoekstra J, de Vos R, van Duijn NP, Schadé E, Bindels PJ. Using the symptom
monitor in a randomized controlled trial: the effect on symptom prevalence and
severity. J Pain Symptom Manage, 2006; 31:22–30. Available at:
https://www.sciencedirect.com/science/article/pii/S0885392405006329 [Last
accessed 15 July 2018]
9. Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H,
Portenoy R. A qualitative study to explore psychological distress and illness
burden associated with opioid induced constipation in cancer patients with
advanced disease. Palliat Med, 2013; 27:447–45. Available at:
http://journals.sagepub.com/doi/abs/10.1177/0269216312450358?journalCode=p
mja [Last accessed 15 July 2018]
10. National Institute for Health and Care Excellence. Opioids in palliative care: safe
and effective prescribing of strong opioids for pain in palliative care of adults,
2012. Available online:www.nice.org.uk/guidance/cg140/resources [Last
accessed 17 October 2017]
11. Merseyside and Cheshire Palliative Care Network Audit Group. Standards and
Guidelines. 4th Edition Liverpool: Merseyside and Cheshire Palliative Care
Network Audit Group; 2010. Available at:
https://www.nwcscnsenate.nhs.uk/files/1714/3394/6186/Constipation.pdf?PDFPA
THWAY=PDF [Last Accessed 15 July 2018[
12. Cheshire and Merseyside Palliative and End of Life Care Network Audit Group.
Guidelines for the Medical Management of Malignant Bowel Obstruction.
Merseyside and Cheshire Palliative Care Network Audit Group; 2016. Available
online:
https://www.nwcscnsenate.nhs.uk/files/3614/9501/7580/Malignant_Bowel_Obstru
ction_2015_FINAL_S__G_NICE.pdf?PDFPATHWAY=PDF [Last accessed 17
October 2017].
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 18
13. Cheshire and Merseyside Palliative and End of Life Care Network Audit Group.
Guideline Development Manual. 2014 (amended 2016) Liverpool. Available
from:
https://www.nwcscnsenate.nhs.uk/files/4914/9501/2099/v1.1Green_Guideline_D
evelopment_Manual_Mar14Amended16_Approved_8Nov16_NICE.pdf?PDFPAT
HWAY=PDF [Last accessed 17th October 2017].
14. Erichsén E, Milberg A, Jaarsma T, Friedrichsen M. Constipation in specialized
palliative care: factors related to constipation when applying different definitions.
Support Care Cancer, 2016; 24: 691-698. Available at:
https://www.mascc.org/assets/Pain_Center/2016_March/march_2016-30.pdf
[Last Accessed 15 July 2018]
15. Expert opinion based on group consensus at the Cheshire and Merseyside
Palliative and End of Life Care Strategic Clinical Network Group Meeting on
16.11.17
16. Department of Constitutional Affairs. Mental Capacity Act 2005 Code of Practice.
London 2007. Available from: www.guardianship.gov.uk [Last accessed 17
October 2017]
17. Mancini IL, Hanson J, Neumann CM, Bruera ED. Opioid Type and Other Clinical
Predictors of Laxative Dose in Advanced Cancer Patients: A Retrospective
Study. J Palliat Med, 2000;3(1):49-55. Available at:
https://mdanderson.elsevierpure.com/en/publications/opioid-type-and-other-
clinical-predictors-of-laxative-dose-in-adv [Last Accessed 15 July 2018]
18. British Dietetic Association. Food Fact Sheet: Fibre. British dietetic association,
2016. Available online: https://www.bda.uk.com/foodfacts/fibre_fact_sheet_poster
[Last accessed 17 October 2017]
19. The Scientific Advisory Committee on Nutrition (SACN). Carbohydrates and
Health. SACN, 2015. Available online:
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/44
5503/SACN_Carbohydrates_and_Health.pdf [Last accessed 17 October 2017]
20. Anti M, Pignatoro G, Armuzzi A, Valenti A, Lascone E, Marmo R, Lamazza A,
Pretaroli AR, Pace V, Leo P, Castelli A, Casbarrini G. Water supplementation
enhances effect of increased fibre diet on stool frequency ad laxative
consumption in adult patients with functional constipation. Hepato-
gastroenterology, 1998; 45: 727-32. Available at:
https://www.researchgate.net/publication/13601287_Water_supplementation_enh
ances_the_effect_of_high-
fiber_diet_on_stool_frequency_and_laxative_consumption_in_adult_patients_wit
h_functional_constipation [Last accessed 15 July 2018]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 19
21. Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B et al. The
management of constipation in palliative care. Clinical practice recommendations.
Palliative Med, 2008; 22: 796-807. Available at:
http://journals.sagepub.com/doi/abs/10.1177/0269216308096908 [Last
acccessed 15 July 2018]
22. Curtis EB, Walsh T. Prescribing Practices of a Palliative Care Service. J Pain
Symptom Manage, 1993; 8:312-316. Available at:
https://www.sciencedirect.com/science/article/pii/088539249390160W [Last
accessed 15 July 2018]
23. Hurdon V, Viola R, Schroder C. How useful is Docusate in Patients at Risk of
Constipation? A Systematic Review of The Evidence in the Chronically Ill. J Pain
Symptom Manage, 2000;19:130-136. Available at:
https://www.jpsmjournal.com/article/S0885-3924(99)00157-8/pdf [Last accessed
15 July 2018
24. Miles C, Fellowes D, Goodman ML, Wilkinson SSM. Laxatives for the
management of constipation in palliative care patients (Review). The Cochrane
Library of Systematic Reviews, 2006; 4: 1-20. Available at: http://cochranelibrary-
wiley.com/doi/10.1002/14651858.CD003448.pub2/abstract [Last accessed 15
July 2018]
25. Tarumi Y, Wilson MP, Szafran O, Richard Spooner G. Randomized, Double-
Blind, Placebo-Controlled Trial of Oral Docusate in the Management of
Constipation in Hospice Patients. J Pain Symptom Manage, 2013; 45(1):2-13.
Available at: https://www.jpsmjournal.com/article/S0885-3924(12)00249-
7/pdf?code=jps-site [Last accessed 15 July 2018]
26. PHARMACEUTICAL PRESS and BMJ GROUP, 2016. British National Formulary
70. London, Pharmaceutical Press.
27. Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of
naloxegol in patients with opioid-induced constipation and laxative-inadequate
response. United European Gastroenterol J, 2015; 3(5): 471-480. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/26535126 [Last accessed 15 July 2018]
28. NICE (National Institute for Health and Care Excellence). 2015. Technology
appraisal guidance [TA345]: Naloxegol for treating opioid‑ induced constipation.
Available online: https://www.nice.org.uk/guidance/ta345/chapter/4-
Consideration-of-the-evidence [Last accessed 15 July 2018]
29. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-
induced bowel dysfunction (Review). Cochrane Library of Systematic Reviews,
2008; 2: 1-54. Available at: http://cochranelibrary-
wiley.com/doi/10.1002/14651858.CD006332.pub2/full [Last acccessed 15 July
2018]
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 20
30. Slatkin NE, Thomas J, Lipman A, Wilson G, Boatwright ML, Wellman C,
Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R.
Methylnaltrexone for Treatment of Opioid-Induced Constipation in Advanced
Illness Patients. J Supp Oncol 2009;7(1):39-46. Available at:
https://mdanderson.elsevierpure.com/en/publications/methylnaltrexone-for-
treatment-of-opioid-induced-constipation-in- [Last accessed 15 July 2018]
31. Twycross, R., Wilcock, A., Howard, P. (Eds.). (2014). Palliative Care Formulary:
5th Edition. Chapter 1: Gastrointestinal system. Pp. 40-59. Nottingham: Palliative
drugs.com
Cheshire and Merseyside Palliative and End of Life Care Strategic Clinical Network Standards and Guidelines
Guidelines for the Management of Constipation in Palliative Care Date of Production: July 2018 Date of Review: July 2021
Page 21
Appendix 1: Systematic Review Summary Form
Guideline Title: Assessment and Management of Constipation in Palliative Care.
Reviewers Monnery D, Ayre R, Owens C, Hyland C, Sudworth G, Devlin L, Edmunds L, Waters L.
IDE
NT
IFIC
AT
ION
E
LIG
IBIL
ITY
IN
CL
UD
ED
S
CR
EE
NIN
G
Records after duplicates removed (n =902)
Records screened (n =1131)
Records remaining after full text review
(n=11) Unrelated to clinical
Question = 3 Not in English language=1
Not fully published = 1
Records remaining after title screening (unrelated
to clinical question) (n = 124)
Articles included in final Guideline Development
(n = 11)
Records remaining after abstract screening
(n =16) Review article = 35 Unrelated to clinical
Question =15 Duplicate record = 57
Case Report = 1
(Constipation AND palliat*) AND (treat* OR Manag*)
Records identified EMBASE (n = 617)
Records identified PubMed (n =58)
What are the best methods of managing constipation in palliative care?
Records identified CINAHL (n =140)
Records identified Medline (n = 331)
Top Related